Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation (NASDAQ: BCPC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global specialty ingredient manufacturer. This SEC filings page aggregates those disclosures, including current reports on Form 8-K and, via EDGAR, the company’s annual reports on Form 10-K, quarterly reports on Form 10-Q and other required filings.
Recent Form 8-K filings show how Balchem uses current reports to furnish quarterly financial results. For example, the company has filed 8-Ks under Item 2.02, “Results of Operations and Financial Condition,” to attach press releases reporting net sales, segment earnings, adjusted EBITDA and free cash flow for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments. Another Form 8-K details the results of Balchem’s annual meeting of shareholders, including director elections, auditor ratification and advisory votes on executive compensation.
Through this page, users can access Balchem’s periodic reports, which typically include segment information, risk disclosures, accounting policies and other data relevant to its specialty ingredients, animal nutrition and specialty chemical activities. Filings related to governance matters, such as shareholder voting outcomes, are also available.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key segment trends and clarify items such as non-GAAP measures referenced in Balchem’s earnings releases. Real-time updates from EDGAR help users see new 10-K, 10-Q and 8-K filings as they are posted, while Form 4 and other ownership-related filings can be reviewed to monitor insider transactions. This combination of official documents and AI-assisted analysis allows investors and researchers to study Balchem’s regulatory history, financial reporting and governance practices in a structured and accessible way.
Balchem Corporation filed its annual report describing a diversified specialty ingredients business across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company serves food, beverage, pharmaceutical, animal health, plant nutrition and industrial markets worldwide.
Backlog was $53,365 thousand at December 31, 2025, modestly above $50,415 thousand a year earlier, with all orders expected to ship in 2026. Balchem invested $43,193 thousand in capital projects and $18,510 thousand in R&D during 2025 to expand capacity, improve efficiency and develop new products.
The company highlights regulatory and environmental exposure around ethylene oxide and propylene oxide, global supply chain and geopolitical risks, cybersecurity threats, labor availability, and raw material inflation. As of year-end 2025 Balchem employed about 1,352 full-time staff worldwide and continued share repurchases, buying back 684,927 shares during 2025.
Balchem Corporation reported strong fourth quarter and full year 2025 results, with broad-based growth across all segments. In Q4 2025, net sales rose 9.8% to
For full year 2025, Balchem delivered record net sales of
Balchem Corporation appointed Erin L. Gilson as Vice President and Chief Accounting Officer, effective April 1, 2026. She succeeds William A. Backus, whose retirement from the same role on March 31, 2026 had been previously announced.
Gilson has been with Balchem since February 2016 and currently serves as Senior Director of Accounting and Financial Reporting. The company states there are no material changes to her compensatory arrangement in connection with this election.
Balchem Corporation senior executive Job Leonard van Gunsteren reported multiple equity compensation transactions. On February 11, 2026, he received 430 shares of restricted stock that vest over three years and 1,345 common shares from vesting performance stock units for the 2023–2025 performance period.
To cover tax obligations upon vesting, 756 shares were withheld at $178.68 per share on February 11 and 58 shares were withheld at $177.49 per share on February 12. He was also granted 1,600 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three. After these transactions he directly owns 10,149 common shares and 1,600 stock options.
Reid Martin Luther reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 7,900 shares at a weighted average price of $178.57 per share. Following the reported transactions, holdings were 9,073 shares.
Harris Theodore L reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 62,743 shares at a weighted average price of $178.58 per share. Following the reported transactions, holdings were 91,373 shares.
BCPC senior executive Graham George reported equity awards from the company. As SVP and Chief R&D Officer, he received a grant of 700 shares of common stock at a price of
The filing also shows a stock option grant for 2,600 shares of common stock with an exercise price of
Backus William A. reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 4,889 shares at a weighted average price of $178.59 per share. Following the reported transactions, holdings were 6,736 shares.
BCPC senior vice president Frederic Boned reported new equity awards and related tax share withholdings. On February 11, he acquired 2,870 shares of restricted common stock and 2,247 common shares from performance stock units vesting for the 2023–2025 period.
To cover tax obligations, 1,151 of those vested shares were withheld at $178.68 per share on February 11 and an additional 203 shares were withheld at $177.49 per share on February 12. He was also granted stock options for 10,500 shares at a $178.68 exercise price, vesting over three years and expiring on February 11, 2036. After these transactions, he directly owned 8,978 common shares, plus 441 shares held indirectly in a 401(k) plan and 10,500 stock options.
BCPC senior vice president and Chief HR Officer Michael Brent Tignor reported multiple equity compensation transactions. On February 11, 2026, he acquired 1,200 shares of restricted common stock at $0, vesting over three years, and 1,929 shares from vested performance stock units for the 2023–2025 period, including 31 dividend equivalent shares.
To cover tax obligations on these vestings, 991 shares were withheld at $178.68 on February 11, 2026 and 165 shares were withheld at $177.49 on February 12, 2026. He also received a stock option for 4,400 shares at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three, expiring on February 11, 2036. Following these transactions he directly held 10,723 common shares, plus 1,456 shares indirectly through a 401(k) plan and 4,400 stock options.